Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Moses Technology vs Vapor Tunnel in Low Power Laser Lithotripsy (MT VT)

10. november 2026 oppdatert av: Polyvios Arseniou, National and Kapodistrian University of Athens

Double Blind Randomized Controlled Trial Comparing Two Distinct Pulse Modulation Modes in Low Power Laser Lithotripsy

The goal of this clinical study is to compare two different laser settings used to break up kidney and ureter stones during surgery. The study will include adults with kidney or ureter stones who are scheduled to undergo a procedure in which an endoscope is passed through the urinary tract and a laser is used to break the stones into smaller pieces.

The main question is whether one laser setting can break up stones using less energy than the other, while maintaining similar treatment effectiveness and safety.

A total of 110 participants will be randomly assigned to one of two groups:

  • One group will undergo stone treatment using Moses Technology.
  • The other group will undergo stone treatment using Vapor Tunnel.

Both methods use a laser to break stones into smaller pieces. The study will compare the amount of laser energy used in relation to the size of the stone. Researchers will also assess the duration of the procedure, how completely the stones are cleared, the movement of stones during surgery, and any complications.

The findings may help urologists understand which laser setting is more efficient and whether it offers advantages during the treatment of kidney and ureter stones.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

110

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Attica
      • Marousi, Attica, Hellas, 15126
        • 2nd Department of Urology, Sismanogleio General Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • kidney/ureter stone
  • maximum stone diameter 5-20 mm (CT)
  • any stone composition
  • recent CT (3 months prior to procedure)
  • indication/no contraindications for laser lithotripsy
  • negative urine culture/adequate antibiotic preparation
  • informed consent

Exclusion Criteria:

  • pregnancy
  • inability/unwillingness to provide informed consent
  • radiolucent stones
  • ipsilateral urinary tract anatomical abnormalities
  • previous non-endoscopic surgery on the urinary tract
  • active urinary tract infection
  • acute kidney injury
  • bleeding disorders
  • inability to discontinue antithrombotic medication when required for the procedure

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Moses Technology

Laser lithotripsy using Moses Technology pulse modulation by Lumenis Pulse 120H Ho:YAG laser system, that produces a two-part laser pulse. The first low-energy part produces a vapor cavity through which the second high-energy part is transmitted to the stone without energy loss, increasing laser efficacy.

Andre navn:
  • Ho:YAG Laser Lithotripsy
Aktiv komparator: Vapor Tunnel

Laser lithotripsy using Vapor Tunnel pulse modulation by Quanta Cyber Ho Ho:YAG laser system, which creates one low-power long-length laser pulse that prevents stone retropulsion.

Andre navn:
  • Ho:YAG Laser Lithotripsy

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Laser efficacy
Tidsramme: During ureteroscopic procedure

Total energy delivered by the Ho:YAG laser during stone lithotripsy, divided by the preoperative stone volume measured on computed tomography (CT). The result will be expressed in joules per cubic millimeter (J/mm³).

During ureteroscopic procedure

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Laser-on time
Tidsramme: During ureteroscopic procedure

The cumulative duration of laser activation during stone lithotripsy, measured in minutes and recorded by the laser system.

During ureteroscopic procedure
Operative time
Tidsramme: During ureteroscopic procedure

The total duration of the ureteroscopic procedure, measured in minutes from the beginning to the completion of the surgical procedure.

During ureteroscopic procedure
Total energy
Tidsramme: During ureteroscopic procedure

The cumulative energy delivered by the Ho:YAG laser during stone lithotripsy, measured in joules (J) and recorded by the laser system.

During ureteroscopic procedure
Lithotripsy rate
Tidsramme: During ureteroscopic procedure

Lithotripsy rate calculated as the preoperative stone volume, measured on CT in cubic millimeters, divided by the total laser activation time in seconds. Results will be expressed in mm³/s.

During ureteroscopic procedure
Stone-free rate
Tidsramme: One month after ureteral stent removal (ureteral stent removal typically removed 7-10 days after discharge)

The proportion of patients with no residual stone fragments larger than 3 mm on postoperative computed tomography (CT).

One month after ureteral stent removal (ureteral stent removal typically removed 7-10 days after discharge)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Intraoperative complications
Tidsramme: During ureteroscopic procedure

The proportion of patients experiencing one or more complications during the ureteroscopic procedure, including their type and nature.

During ureteroscopic procedure
Postoperative complications
Tidsramme: Within 30 days after the ureteroscopic procedure

The proportion of patients experiencing postoperative complications, including their type and severity, classified according to the Clavien-Dindo classification system.

Within 30 days after the ureteroscopic procedure
Length of hospital stay
Tidsramme: From hospital admission until discharge

The duration of hospitalization, calculated as the number of days from hospital admission to hospital discharge.

From hospital admission until discharge
Stone retropulsion
Tidsramme: During ureteroscopic procedure

Surgeon-assessed stone retropulsion during laser lithotripsy, evaluated according to the distance of stone displacement, frequency of retropulsion events, and impact of retropulsion on the completion of stone fragmentation.

During ureteroscopic procedure

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. november 2027

Studiet fullført (Antatt)

1. oktober 2029

Datoer for studieregistrering

Først innsendt

3. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere